Lcarpro 500mg Tablet contains Levo-carnitine, an active compound essential for the transport of long-chain fatty acids into the mitochondria, facilitating energy production through beta-oxidation. This medication is primarily indicated for the treatment of primary and secondary carnitine deficiency, which may result from metabolic disorders, genetic conditions, or acquired states such as chronic renal failure and certain drug therapies. Lcarpro supports cellular energy metabolism, particularly in muscle and cardiac tissues, where energy demand is high. It is also utilized as an adjunct therapy in conditions characterized by impaired fatty acid oxidation, including some neuromuscular diseases and cardiomyopathies. The recommended dosage and duration of treatment should be individualized based on the patient’s clinical condition and response to therapy. Lcarpro is generally well tolerated; however, adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and abdominal cramps. Caution is advised in patients with hypothyroidism or seizure disorders. Regular monitoring of carnitine levels and clinical status is recommended during prolonged therapy. Lcarpro 500mg Tablet should be used under medical supervision to ensure efficacy and safety in managing carnitine deficiency and related metabolic conditions.